Abiomed, Inc. - ABMD STOCK NEWS

Abiomed (NASDAQ: ABMD) has appointed Dr. Myron Rolle to its Board of Directors, effective immediately. Dr. Rolle, a neurosurgeon and Rhodes scholar, will serve on the Governance and Nominating Committee and the Regulatory and Compliance Committee, expanding the board to eight directors. His experience in medical technology and public health is expected to enhance the company's mission to address health disparities. Dr. Rolle emphasized his commitment to improving patient outcomes and extending access to Abiomed's life-saving technologies.

Abiomed, Inc (NASDAQ: ABMD) announced that CEO Michael R. Minogue will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 8:40 AM ET and the Raymond James 2021 Institutional Investors Conference on March 2 at 10:50 AM ET. Abiomed, based in Danvers, Massachusetts, specializes in medical devices that provide circulatory support, enhancing blood flow and heart function. The company emphasizes its commitment to innovation in heart support technologies.

Abiomed (NASDAQ: ABMD) has released findings from a significant study involving 356 patients treated with Impella 5.5 with SmartAssist at 16 centers in the U.S. and Germany, revealing a remarkable 79% survival rate at explant. Notably, most surviving patients regained native heart function without needing additional mechanical support. The results were presented at the STS 2021 Annual Meeting, confirming the device's promising outcomes in critically ill cardiogenic shock patients. Future studies are anticipated to further explore its clinical effectiveness.

Abiomed, Inc. (NASDAQ: ABMD) reported record revenue of $231.7 million for Q3 fiscal 2021, a 5% year-over-year increase despite COVID-19 challenges. Operating income rose to $71.4 million, up 2%. Impella® product revenue reached $220.8 million, with U.S. sales at $179.6 million, a 1% increase. Notably, international revenues grew significantly, with Japan achieving a 38% rise. Gross margin improved to 82.3%. However, GAAP net income declined to $61.9 million from $69.2 million. The company forecasts Q4 2021 revenue between $225 million and $235 million, reflecting 9-14% growth.

Abiomed, Inc. (NASDAQ: ABMD) will release its financial results for Q3 of fiscal 2021 on January 28, 2021, at 8:00 a.m. ET. Chairman and CEO Michael R. Minogue, along with CFO Todd Trapp, will host a conference call to discuss the results. Stakeholders can access the live call through a webcast or by phone. A replay will be available from January 28 at 11:00 a.m. ET until February 4, 2021. Abiomed specializes in medical devices that support circulatory health.

Abiomed (NASDAQ: ABMD) has achieved a significant milestone by surpassing 1,000 patents worldwide, with over 850 additional patents pending. This extensive intellectual property portfolio safeguards its innovative pump and catheter designs, along with components like motors and software. The company has invested over $600 million in R&D over the past 20 years, underscoring its commitment to technology and innovation. Abiomed aims to develop smaller, smarter technologies that enhance patient care, led by a dedicated team of engineers and scientists across its global facilities.

Abiomed, Inc. (NASDAQ: ABMD) announced that Michael R. Minogue, Chairman, President, and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 5:20 PM EST. A live webcast of this presentation can be accessed via the JPMorgan Abiomed Webcast. The presentation will also be available on the company’s investor website.

Abiomed (NASDAQ: ABMD) reports the treatment of the first two patients in the world with its Breethe OXY-1 System, a novel cardiopulmonary bypass device. The system aids patients suffering from respiratory failure by pumping, oxygenating, and removing carbon dioxide from blood. The first patient, a 21-year-old woman, showed significant recovery and was weaned off the system after eight days. The second patient, a 51-year-old woman, is also stable after 24 hours of support. Breethe received FDA 510(k) clearance in October and will be commercially available in 2021.

Abiomed (NASDAQ: ABMD) has successfully hit two key milestones in the development of its Impella heart pump. The Impella ECP heart pump has cleared the first stage of the FDA's early feasibility study, enrolling five patients, while the company has received 510(k) clearance for the Impella XR sheath. The XR sheath allows for small bore access, reducing trauma at the arterial access site. The Impella ECP pump, measuring just 9 Fr, aims to improve care for high-risk PCI patients. Abiomed plans to submit data to the FDA for the next stage of the study.